These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 37097712)

  • 21. Brief communication: rituximab in HIV-associated multicentric Castleman disease.
    Bower M; Powles T; Williams S; Davis TN; Atkins M; Montoto S; Orkin C; Webb A; Fisher M; Nelson M; Gazzard B; Stebbing J; Kelleher P
    Ann Intern Med; 2007 Dec; 147(12):836-9. PubMed ID: 18087054
    [TBL] [Abstract][Full Text] [Related]  

  • 22. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease.
    van Rhee F; Voorhees P; Dispenzieri A; Fosså A; Srkalovic G; Ide M; Munshi N; Schey S; Streetly M; Pierson SK; Partridge HL; Mukherjee S; Shilling D; Stone K; Greenway A; Ruth J; Lechowicz MJ; Chandrakasan S; Jayanthan R; Jaffe ES; Leitch H; Pemmaraju N; Chadburn A; Lim MS; Elenitoba-Johnson KS; Krymskaya V; Goodman A; Hoffmann C; Zinzani PL; Ferrero S; Terriou L; Sato Y; Simpson D; Wong R; Rossi JF; Nasta S; Yoshizaki K; Kurzrock R; Uldrick TS; Casper C; Oksenhendler E; Fajgenbaum DC
    Blood; 2018 Nov; 132(20):2115-2124. PubMed ID: 30181172
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aseptic Meningitis-retention Syndrome Associated with Tocilizumab in a Patient with Idiopathic Multicentric Castleman Disease.
    Arakawa A; Iizuka M; Matsuda S; Matsubara E; Yamazaki H; Yoshikawa N; Tanaka H; Yoshizawa T
    Intern Med; 2021 Dec; 60(24):3995-3998. PubMed ID: 34219105
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Daratumumab for the treatment of refractory idiopathic multicentric Castleman disease: a case report.
    Shi Y; Li J; Zhang L
    Ann Hematol; 2022 Nov; 101(11):2529-2531. PubMed ID: 35927344
    [No Abstract]   [Full Text] [Related]  

  • 25. Deriving health utility values from a randomized, double-blind, placebo-controlled trial of siltuximab in subjects with multicentric Castleman's disease.
    Vernon M; Robinson D; Trundell D; Ishak J; Jen MH; Brazier J
    Curr Med Res Opin; 2016 Jul; 32(7):1193-200. PubMed ID: 26972925
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Afebrile Pneumonia in a Patient With Multicentric Castleman Disease on Siltuximab: Infection Without Fever on Anti-Interleukin-6 Therapy.
    Cohen PR; Nikanjam M; Kato S; Goodman AM; Kurzrock R
    Cureus; 2020 Jul; 12(7):e8967. PubMed ID: 32766009
    [TBL] [Abstract][Full Text] [Related]  

  • 27. JAK1 Genomic Alteration Associated With Exceptional Response to Siltuximab in Cutaneous Castleman Disease.
    Patel M; Ikeda S; Pilat SR; Kurzrock R
    JAMA Dermatol; 2017 May; 153(5):449-452. PubMed ID: 28241173
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Frontline Siltuximab and Rituximab in TAFRO syndrome: A case report.
    Marchetti M; Feyles E; Zinzani P
    Eur J Haematol; 2020 Oct; 105(4):505-507. PubMed ID: 32564425
    [No Abstract]   [Full Text] [Related]  

  • 29. Effectiveness of rituximab-containing treatment regimens in idiopathic multicentric Castleman disease.
    Dong Y; Zhang L; Nong L; Wang L; Liang Z; Zhou D; Fajgenbaum DC; Ren H; Li J
    Ann Hematol; 2018 Sep; 97(9):1641-1647. PubMed ID: 29732477
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of regimens used for the treatment of multicentric Castleman disease: A systematic review.
    Rehman MEU; Chattaraj A; Neupane K; Rafae A; Saeed S; Basit J; Ibrahim A; Khouri J; Mukherjee S; Anwer F
    Eur J Haematol; 2022 Oct; 109(4):309-320. PubMed ID: 35770616
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Idiopathic multicentric Castleman disease treated with siltuximab for 15 years: a case report.
    Lang E; Sande B; Brodkin S; van Rhee F
    Ther Adv Hematol; 2022; 13():20406207221082552. PubMed ID: 35251585
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.
    Fajgenbaum DC
    Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):318-325. PubMed ID: 30504327
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease.
    Zhang L; Zhao AL; Duan MH; Li ZY; Cao XX; Feng J; Zhou DB; Zhong DR; Fajgenbaum DC; Li J
    Blood; 2019 Apr; 133(16):1720-1728. PubMed ID: 30760451
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease.
    Fajgenbaum DC; Wu D; Goodman A; Wong R; Chadburn A; Nasta S; Srkalovic G; Mukherjee S; Leitch H; Jayanthan R; Ferrero S; Sato Y; Schey S; Dispenzieri A; Oksenhendler E; Zinzani PL; Lechowicz MJ; Hoffmann C; Pemmaraju N; Bagg A; Fossa A; Lim MS; van Rhee F;
    Am J Hematol; 2020 Dec; 95(12):1553-1561. PubMed ID: 32894785
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Unicentric Castlemans disease. Symptoms, diagnostics and therapy].
    Adam Z; Řehák Z; Adamová Z; Koukalová R; Pour L; Krejčí M; Boichuk I; Krejčí M; Štork M; Ševčíková S; Král Z
    Vnitr Lek; 2021; 67(8):465-473. PubMed ID: 35459366
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease.
    Pierson SK; Shenoy S; Oromendia AB; Gorzewski AM; Langan Pai RA; Nabel CS; Ruth JR; Parente SAT; Arenas DJ; Guilfoyle M; Reddy M; Weinblatt M; Shadick N; Bower M; Pria AD; Masaki Y; Katz L; Mezey J; Beineke P; Lee D; Tendler C; Kambayashi T; Fosså A; van Rhee F; Fajgenbaum DC
    Blood Adv; 2021 Sep; 5(17):3445-3456. PubMed ID: 34438448
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Siltuximab: a targeted therapy for idiopathic multicentric Castleman disease.
    Fajgenbaum DC; Kurzrock R
    Immunotherapy; 2016; 8(1):17-26. PubMed ID: 26634298
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Siltuximab: A Review in Idiopathic (Human Herpesvirus-8-Negative) Multicentric Castleman Disease.
    Lyseng-Williamson KA
    BioDrugs; 2015 Dec; 29(6):399-406. PubMed ID: 26394632
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effects of interleukin-6 neutralizing antibodies on symptoms of depressed mood and anhedonia in patients with rheumatoid arthritis and multicentric Castleman's disease.
    Sun Y; Wang D; Salvadore G; Hsu B; Curran M; Casper C; Vermeulen J; Kent JM; Singh J; Drevets WC; Wittenberg GM; Chen G
    Brain Behav Immun; 2017 Nov; 66():156-164. PubMed ID: 28676350
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rituximab as retreatment for rituximab pretreated HIV-associated multicentric Castleman disease.
    Powles T; Stebbing J; Montoto S; Nelson M; Gazzard B; Orkin C; Webb A; Bower M
    Blood; 2007 Dec; 110(12):4132-3. PubMed ID: 18024800
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.